Impact of long-acting therapies on the global HIV epidemic

Chandiwana, Nomathemba C, Serenata, Celicia M, Owen, Andrew ORCID: 0000-0002-9819-7651, Rannard, Steve ORCID: 0000-0002-6946-1097, Casas, Carmen Perez, Scott, Cherise, Hill, Andrew, Clayden, Polly and Flexner, Charles
(2021) Impact of long-acting therapies on the global HIV epidemic. AIDS, 35 (Suppl ). S137-S143.

Access the full-text of this item by clicking on the Open Access link.


Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current daily-based oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.

Item Type: Article
Uncontrolled Keywords: access and barriers, long-acting antiretrovirals, low-income and middle-income countries, treatment optimization
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Faculty of Science and Engineering > School of Physical Sciences
Depositing User: Symplectic Admin
Date Deposited: 11 Feb 2022 10:22
Last Modified: 18 Jan 2023 21:12
DOI: 10.1097/QAD.0000000000003102
Open Access URL:
Related URLs: